Abstract 11174: Effect of APOCIII-LRxon Lipoprotein Size and Particle Numbers Measured by NMR in Patients with Hypertriglyceridemia: Results of the AKCEA-APOCIII-LRx Trial

Ewa Karwatowska-Prokopczuk,Jean-Claude Tardif,Daniel Gaudet,Christie M. Ballantyne,Michael D. Shapiro,Patrick M. Moriarty,Seth J. Baum,Eric St-Amour,Vickie Alexander,Shuting Xia,James D. Otvos,Joseph L. Witztum,Sotirios Tsimikas

Abstract 11174: Effect of APOCIII-LRxon Lipoprotein Size and Particle Numbers Measured by NMR in Patients with Hypertriglyceridemia: Results of the AKCEA-APOCIII-LRx Trial

2021

Ewa Karwatowska-Prokopczuk
Jean-Claude Tardif
Daniel Gaudet
Christie M. Ballantyne
Michael D. Shapiro
Patrick M. Moriarty
Seth J. Baum
Eric St-Amour
Vickie Alexander
Shuting Xia
James D. Otvos
Joseph L. Witztum
Sotirios Tsimikas

Background: APOCIII-LRx is a hepatocyte-targeted, GalNAc-modified antisense oligonucleotide that decreases plasma levels of apoC-III and triglyceride-rich lipoproteins (TRLs). We examined the effec...

Keywords:

plasma levels
Lipoprotein
Hyperlipidemia
Internal medicine
Endocrinology
Hypertriglyceridemia
antisense oligonucleotides
Medicine
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations